The agency is investigating four unidentified medical colleges and hospitals for alleged workforce discrimination based on race, color, national origin and sex.
Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its official shortage list arbitrarily and without warning.